Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196791 | 0.73 | KDM4E (0.30) | KDM4ECYP1A2LMNA | |
| SCHEMBL6617218 | 0.73 | KDM4E (0.48) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Water SCHEMBL28200435 | 0.72 | KDM4E (0.59) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL17701185 | 0.72 | PIM1 (0.35) | KDM4EALDH1A1MAPTNPC1SMN1; SMN2 | |
| SCHEMBL971977 | 0.72 | KDM4E (0.50) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL27722994 | 0.71 | NPC1 (0.40) | KDM4EALDH1A1HPGDMAPTNPC1 | |
| Ammonia Solution, Strong SCHEMBL28220199 | 0.71 | KDM4E (0.57) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL30596386 | 0.69 | KDM4E (0.61) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL36011 | 0.69 | KDM4E (0.61) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL745903 | 0.69 | HSP90AA1 (0.44) | RAB9ACYP1A2ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111778-A1 | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | claimed |
| EP-1954137-A4 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-17 | — | — | EP | claimed |
| EP-1954137-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061862-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | WO | claimed |
| CN-1304415-C | Pyrane derivatives as both ACE- and NEP- inhibitors | NOVARTIS AG (CH) | 2007-03-14 | — | — | CN | claimed |
| EP-1430045-B1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | NOVARTIS AG (CH) | 2006-10-11 | — | — | EP | claimed |
| US-7071169-B2 | Pyrane derivatives as both ACE-and NEP-inhibitors | NOVARTIS AG (CH) | 2006-07-04 | — | — | US | claimed |
| EP-1080104-B1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | claimed |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | FINK CYNTHIA ANNE (US) | 2004-12-30 | — | — | US | claimed |
| CN-1555372-A | Pyrane derivatives as both ace- and nep- inhibitors | ��˹��ŵ�� | 2004-12-15 | — | — | CN | claimed |
| EP-1430045-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | Novartis AG (CH) | 2004-06-23 | — | — | EP | claimed |
| US-6689801-B2 | CARDIOVASCULAR DISORDERS; ANTIISCHEMIC AGENTS; HYPOTENSIVE AGENTS; GASTROINTESTINAL DISORDERS | NOVARTIS AG (CH) | 2004-02-10 | — | — | US | claimed |
| WO-2003027091-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS | NOVARTIS AG (CH) | 2003-04-03 | — | — | WO | claimed |
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | FINK CYNTHIA ANNE (US) | 2003-01-23 | — | — | US | claimed |
| US-6426354-B1 | CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS; BRAIN DISORDERS | NOVARTIS AG (CH) | 2002-07-30 | — | — | US | claimed |
| EP-1080104-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-03-07 | — | — | EP | claimed |
| WO-1999055723-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | claimed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-1080104-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999055723-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | KDM4E 2634/4885ALDH1A1 145/4885HPGD 182/4885 |
| US-20090111778-A1 | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase | FAAH, FAAH2, HCRTR2 | KDM4E 150/4885ALDH1A1 820/4885HPGD 794/4885 |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | ECE1, AGTR1, ACE | KDM4E 1267/4885ALDH1A1 141/4885HPGD 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.